Irreversible electroporation versus radiofrequency ablation for malignant hepatic tumor: A prospective single-center double-arm trial
- PMID: 35936662
- PMCID: PMC9349015
- DOI: 10.1016/j.jimed.2022.03.010
Irreversible electroporation versus radiofrequency ablation for malignant hepatic tumor: A prospective single-center double-arm trial
Abstract
Objective: Irreversible electroporation (IRE) is a nonthermal ablation technique for the treatment of malignant liver tumors. IRE has demonstrated efficacy and safety in the treatment of malignant liver tumors and its unique advantages in the treatment of nearby vascular lesions. This study aimed to compare the efficacy, safety, and intermediate-term outcomes of IRE and radiofrequency (RF) therapy in malignant liver tumors.
Methods: Twenty-four patients with primary or secondary liver malignancies were included in this prospective, double-arm clinical trial. Patients were randomly divided into the IRE and RF groups. The primary outcome was the efficacy (local ablation control evaluation at 90 days). The secondary outcomes were safety (procedure-related complications at ≤ 90 days) and intermediate-term survival (at 24 months).
Results: The ablation assessment at 90 days after surgery with mRECIST for IRE versus RF were 70%, 20%, 0%, and 10% versus 92.9%, 7.1%, 0%, and 0% (CR, PR, SD, and PD, respectively). The complication rates of IRE versus RF with Clavien-Dindo classification were 16.7%, 25%, 0%, 8.3%, and 8.3% versus 8.3%, 50%, 0%, 0%, and 0% (Grade I, II, III, IV, and V, respectively). The average overall survival (OS) was 17.55 months in the IRE group (95% CI 15.13-22.37) and 18.75 months in the RF group (95% CI 12.48-22.61). There was no statistical difference between the IRE and RF groups in terms of efficacy (p = 0.48), safety(p = 0.887), or 24-month OS (p = 0.959).
Conclusions: IRE ablation revealed similar efficacy and safety in a short-term follow-up, and similar OS in mid-term survival as RF ablation in treating malignant hepatic tumors.
Keywords: Efficacy; Intermediate-term survival; Irreversible electroporation; Prospective trial; Radiofrequency ablation.
© 2022 Shanghai Journal of Interventional Radiology Press. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures




Similar articles
-
Novel irreversible electroporation ablation (Nano-knife) versus radiofrequency ablation for the treatment of solid liver tumors: a comparative, randomized, multicenter clinical study.Front Oncol. 2022 Sep 29;12:945123. doi: 10.3389/fonc.2022.945123. eCollection 2022. Front Oncol. 2022. PMID: 36249062 Free PMC article.
-
Irreversible Electroporation versus Radiofrequency Ablation: A Comparison of Local and Systemic Effects in a Small-Animal Model.Radiology. 2016 Aug;280(2):413-24. doi: 10.1148/radiol.2015151166. Epub 2016 Jan 27. Radiology. 2016. PMID: 27429143
-
Irreversible Electroporation versus Radiofrequency Ablation: Comparison of Systemic Immune Responses in Patients with Hepatocellular Carcinoma.J Vasc Interv Radiol. 2019 Jun;30(6):845-853.e6. doi: 10.1016/j.jvir.2019.03.002. J Vasc Interv Radiol. 2019. PMID: 31126596
-
The debate between electricity and heat, efficacy and safety of irreversible electroporation and radiofrequency ablation in the treatment of liver cancer: A meta-analysis.Open Life Sci. 2024 Dec 18;19(1):20220991. doi: 10.1515/biol-2022-0991. eCollection 2024. Open Life Sci. 2024. PMID: 39711974 Free PMC article. Review.
-
Irreversible electroporation for the ablation of liver tumors: are we there yet?Arch Surg. 2012 Nov;147(11):1053-61. doi: 10.1001/2013.jamasurg.100. Arch Surg. 2012. PMID: 23165618 Review.
Cited by
-
Irreversible Electroporation of the Hepatobiliary System: Current Utilization and Future Avenues.Medicina (Kaunas). 2024 Jan 31;60(2):251. doi: 10.3390/medicina60020251. Medicina (Kaunas). 2024. PMID: 38399539 Free PMC article. Review.
-
Recent Advances in Ablative Therapies for HCC.J Clin Exp Hepatol. 2025 Sep-Oct;15(5):102592. doi: 10.1016/j.jceh.2025.102592. Epub 2025 May 17. J Clin Exp Hepatol. 2025. PMID: 40535845 Review.
References
-
- Davalos R.V., Mir I.L., Rubinsky B. Tissue ablation with irreversible electroporation. Ann Biomed Eng. 2005;33:223–231. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials